VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)
VIEKIRA PAK is a brand-name prescription drug that’s FDA-approved to treat genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis. Brand Name: VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Initial U.S. Approval: 2014
Home | (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets
Ombitasvir/paritaprevir/ritonavir is used together with dasabuvir or ribavirin for cases caused by hepatitis C virus genotype 1 or 4. Cure rates are around 95%. Ombitasvir/paritaprevir/ritonavir with dasabuvir was approved for medical use in the United States in 2014, and without dasabuvir in 2015.
VIEKIRA PAK with or without ribavirin is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis. VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
Ombitasvir/paritaprevir/ritonavir, sold under the brand name Technivie among others, is a medication used to treat hepatitis C. It is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir. The regimen ombitasvir-paritaprevir-ritonavir plus dasabuvir is FDA-approved for the treatment of chronic hepatitis C genotype 1, including those with compensated cirrhosis. The recommendations for use of the Viekira Pak refer to a dosing regimen of 2 tablets once daily of the fixed-dose combination ombitasvir-paritaprevir-ritonavir plus one tablet twice daily of dasabuvir. The regimen ombitasvir-paritaprevir-ritonavir plus dasabuvir is approved for use in both treatment-naive and treatment-experienced patients.
On December 19, 2014, the United States FDA approved ombitasvir-paritaprevir-ritonavir and dasabuvir for the treatment of genotype 1 chronic hepatitis C infection in adults, including patients with compensated cirrhosis. The medications ombitasvir, paritaprevir, and dasabuvir do not have FDA approval for use as individual drugs outside of use in the Viekira Pak. The drug ritonavir was previously approved by the FDA for use as an HIV protease inhibitor.
Drug (Brand / Generic):VIEKIRA PAK / ombitasvir, paritaprevir, and ritonavir
Current Indications: genotype 1 chronic hepatitis C virus (HCV) infection
Marketed by:: AbbVie Inc.
Approval Date: October 27, 2014
Available as (Form & Strength):
• Ombitasvir, paritaprevir, ritonavir: 12.5/75/50 mg
• Dasabuvir: 250 mg
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)”.
Confirmation of the order for VIEKIRA PAKwill be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand VIEKIRA PAK. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to VIEKIRA PAK, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.